Brief: Sernova And Evotec Enter Into An Exclusive Global Strategic Partnership For IPSC-Based Beta Cell Replacement Therapy
17/05/2022 12:14
May 17 (Reuters) - Evotec SE EVTG.DE :
* SERNOVA AND EVOTEC ENTER INTO AN EXCLUSIVE GLOBAL STRATEGIC PARTNERSHIP
FOR
IPSC-BASED BETA CELL REPLACEMENT THERAPY TO DEVELOP AND COMMERCIALIZE A
‘FUNCTIONAL CURE’ FOR DIABETES
* SERNOVA CORP - COS WILL COMBINE TECHNOLOGIES & SCIENTIFIC EXPERTISE TO
DEVELOP
IMPLANTABLE IPSC-BASED BETA CELL REPLACEMENT THERAPY
Source text for Eikon: ID:nGNX7PY3Df
Further company coverage: EVTG.DE
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sernova Biotherapeutics
See all newsBrief: Seraxis And Sernova Announce Appointment Of Former FDA Medical Officer Dr. Patricia Beaston As Chief Medical Officer Of Seraxis And Post Merger Betanova Biotherapeutics
Brief: Sernova Appoints Jonathan Rigby As Interim Chair
Brief: Sernova Biotherapeutics Provides Positive Interim Data From Ongoing Phase 1/2 Clinical Trial Of Cell Pouch Bio-Hybrid Organ In Patients Living With Type 1 Diabetes
Brief: Sernova Biotherapeutics Secures $4 Million Loan To Further Advance Its Clinical Development Plans
Brief: Sernova Biotherapeutics Inc Study Is On Track To Meet Key Clinical Trial Endpoints